Aldeyra Therapeutics Goes Ahead with Reproxalap for Dry Eye Disease
Aldeyra Therapeutics Inc. (ALDX) reported that it has struck a deal with the FDA for the use of Reactive Aldehyde Species or RASP for the treating dry eye disease. The agreement has been reached on the basis of meetings, discussions and preliminary written comments. The company stated that it plans to provide further updates on its development plans and submitting NDA obligations for reproxalap in dry eye disease in July 2020.
Aldeyra is currently working on reproxalap, which is its first in class